[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ankylosing-spondylitis-as\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ankylosing-spondylitis-as":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,48,77,106,126,146,161,185,209,296,324,347,367,395,417,443],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643716","an-investigation-of-the-effect-of-smartphone-usage-levels-on-cervical-posture-tongue-pressure-balance-and-neck-disability-in-individuals-with-rheumatoid-arthritis-and-ankylosing-spondylitis-100643716",false,"NCT07627542","An Investigation of the Effect of Smartphone Usage Levels on Cervical Posture, Tongue Pressure, Balance, and Neck Disability in Individuals With Rheumatoid Arthritis and Ankylosing Spondylitis","Inclusion Criteria:\n\n* Aged 18 to 65 years.\n* Using a smartphone for at least 2 hours daily.\n* Able to understand and follow postural commands during clinical measurements.\n* For the Rheumatoid Arthritis (RA) Group: Diagnosed with RA by a rheumatologist, with a stable disease activity score (DAS28 \\\u003C 3.2).\n* For the Ankylosing Spondylitis (AS) Group: Diagnosed with AS by a rheumatologist, with a stable disease activity score (BASDAI \\\u003C 4).\n\nExclusion Criteria:\n\n* History of prior surgical intervention in the cervical region.\n* Presence of neurological diseases (e.g., Parkinson's disease, ALS).\n* Severe visual or hearing impairment.\n* Vestibular system disorders.\n* Severe limitation in jaw opening.\n* Presence of acute neck trauma or malignancy.\n* Lower extremity amputation or advanced arthritis that prevents performing the balance test.\n* Active use of muscle relaxants or advanced sedative medications.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},111,"ESTIMATED","OBSERVATIONAL","The purpose of this cross-sectional and comparative study is to investigate the impact of smartphone addiction on the cervical posture, musculoskeletal system, balance, and tongue pressure in individuals diagnosed with Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), and to compare these findings with a healthy control group. Smartphone addiction has become a major contributing factor to postural alterations such as Text Neck Syndrome. This study aims to evaluate and compare the Craniovertebral Angle (CVA), neck extensor muscle strength, Pressure Pain Thresholds (PPT) of the neck and shoulder, Single-Leg Stance (SLS) static balance, and tongue pressure among three distinct groups. A healthy control group will be included as a reference baseline to differentiate the postural and functional deterioration caused by rheumatological diseases from the additional mechanical load imposed by smartphone dependency. To eliminate the misleading effects of acute pain, joint swelling, and severe functional limitations during flare-ups, only patients with stable disease activity (DAS28 \\\u003C 3.2 for RA and BASDAI \\\u003C 4 for AS) will be enrolled. This approach aims to examine the pure biomechanical relationship between technological dependency and cervical functions, independent of active systemic inflammation.",[25,26,27],"Rheumatoid Arthritis (RA)","Ankylosing Spondylitis (AS)","Forward Head Posture",[29,30,31,32,33,34],"Text Neck","Smartphone Addiction","Neck Pain","Postural Balance","Neck Muscle Strength","Tongue Pressure","RECRUITING","2026-06-05",{"date":38,"type":39},"2026-06-09","ACTUAL",{"date":41,"type":39},"2026-04-09",{"date":43,"type":21},"2026-11",{"name":45,"class":46},"Merve Şahin","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100643353","efficacy-of-the-erector-spinae-plane-block-for-persistent-back-pain-in-patients-with-ankylosing-spondylitis-100643353","NCT07633730","Efficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of ankylosing spondylitis according to the Modified New York Criteria\n* Patients receiving ongoing treatment with controlled disease activity but persistent back pain\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Body mass index (BMI) greater than 35 kg\u002Fm²\n* History of thoracic surgery\n* Intellectual disability or mental retardation\n* Presence of major psychiatric comorbidity\n* Congenital spinal anomaly\n* Pregnancy\n* History of bleeding diathesis\n* Presence of active local and\u002For systemic infection\n* Known allergy to the medications to be injected\n* Hemodynamic instability\n* Active phase of the disease (elevated acute phase reactants, active arthritis findings, etc.)",{"count":55,"type":21},15,"INTERVENTIONAL",[58],"NA","Despite adequate control of disease activity with standard medical therapies, there remains an ongoing need for complementary and interventional approaches for the management of persistent back pain in patients with ankylosing spondylitis. Although the erector spinae plane block has been described in the literature as a safe and effective analgesic intervention for chronic back pain in various patient populations, to the best of our knowledge, no clinical study has specifically evaluated its use for persistent back pain in patients with ankylosing spondylitis receiving medical treatment. Therefore, the present study aims to evaluate the effects of erector spinae plane block on pain severity and clinical outcomes in patients with ankylosing spondylitis whose disease activity is controlled under treatment but who continue to experience persistent back pain.",[26,61,62,63],"Back Pain","ESPB","Regional Anesthesia",[62,65,61,66,67,68],"Erector Spinae Plane Block","Ankylosing Spondylitis","Persistent back pain","Regional anesthesia","2026-06-02",{"date":71,"type":39},"2026-06-08",{"date":69,"type":39},{"date":74,"type":21},"2027-06-02",{"name":76,"class":46},"Marmara University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100634195","oxidative-stress-in-autoimmune-rheumatic-diseases-100634195","NCT07536529","Oxidative Stress in Autoimmune Rheumatic Diseases","Investigation of the Role of Redox Status of Patients With Autoimmune Rheumatic Diseases on Disease Progression: An Epidemiological Study","REDOX-ARD","Inclusion Criteria:\n\n* Adult patients (\\>18 years old), with a primary diagnosis of rheumatoid arthritis using the criteria of American College of Rheumatology (ACR)\n* Adult patients (\\>18 years old), with a primary diagnosis of psoriatic arthritis using the ClASsification criteria for Psoriatic Arthritis (CASPAR)\n* Adult patients (\\>18 years old), with a primary diagnosis of alkylosing spondyloarthritis using the criteria of Assessment of SpondyloArthritis international Society (ASAS) group\n* Adult patients (\\>18 years old) irrespective of gender\n* Adult patients (\\>18 years old) irrespective of ethnicity\n* Adult patients (\\>18 years old) irrespective of comorbidities\n* Adult patients (\\>18 years old) irrespective of socioeconomic background\n* Adult patients (\\>18 years old) with any disease status\n* Adult patients (\\>18 years old) with any disease duration\n* Adult patients (\\>18 years old) under any treatment scheme (e.g. non-steroidal anti-inflammatory drugs, steroids, disease-modifying anti-rheumatic drugs including biologics)\n\nExclusion Criteria:\n\n* Adult patients (\\>18 years old) with concurrent infectious disease\n* Adult patients (\\>18 years old) in pregnancy\n* Patients under 18 years of age",{"count":86,"type":21},200,"Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, Sjogren's syndrome and systemic scleroderma. These autoimmune disorders lead to joint destruction and adversely influence the human body systemically. One of their characteristics is comorbidity, since patients usually suffer also from other pathologies such as cardiovascular diseases and obesity. In addition, their treatment requires a combination of both biological and conventional pharmaceutical interventions as well as other parameters such as physical activity programs, nutrition, and the use of smart electronic devices. Therefore, the ARDs burden health systems worldwide. Apart from the physiological manifestations of ARDs, specific changes are observed at the cellular and molecular level. A common biochemical\u002Fmolecular symptom of these diseases is oxidative stress. This condition leads to the disturbance of blood and tissue redox status due to the excessive production of free radicals. Given that free radicals are highly reactive moieties with strong oxidative capacity against biomolecules (i.e., proteins, lipids, DNA), they compromise the efficacy of the intrinsic antioxidant mechanisms and, finally, induce the disruption of redox homeostasis. However, there is no sufficient data linking the levels of redox status of patients with the progression of ARDs over time. Indeed, the onset and symptoms of ARDs are intertwined with the disruption of the patient redox homeostasis and the induction of oxidative stress. Concurrently, the absence of a completely effective pharmaceutical treatment emerges the need for the adoption of novel biomarkers for monitoring the severity of the symptoms and the evolution of ARDs in general. To that end, this study aims at first to investigate the blood redox status of patients with ARDs. Thus, specific redox biomarkers will be evaluated in the blood of patients in three time points (i.e., at Days 1, 180 and 360), and they will be associated with the clinical manifestations of their diseases. The ultimate goal is to clarify whether these biomarkers could putatively exert clinical significance, namely whether they could constitute an additional tool for the monitoring of the progression of these diseases in clinical practice.",[89,25,90,26],"Inflammatory Joint Diseases","Psoriatic Arthritis (PsA)",[92,93,94,95,96],"Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Oxidative stress","Antioxidants","2026-04-22",{"date":99,"type":39},"2026-04-28",{"date":101,"type":39},"2025-10-06",{"date":103,"type":21},"2026-10",{"name":105,"class":46},"University of Thessaly",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100635710","evaluating-the-efficacy-and-short-term-prognosis-of-integrated-traditional-chinese-and-western-medicine-for-ankylosing-spondylitisas-a-protocol-for-a-cohort-study-100635710","NCT07556224","Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Cohort Study","Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n* fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis\n* age between 18 and 75 years\n* sign informed consent.\n\nExclusion Criteria:\n\n* diagnosis of other autoimmune diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.)\n* pregnancy or lactation\n* comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or malignancy\n* spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis\n* unable to provide data due to mental, language, or similar factors.","75 Years",{"count":115,"type":21},790,"This study is a multicenter, prospective cohort study designed to systematically evaluate the clinical efficacy of integrated Traditional Chinese and Western Medicine on short-term functional improvement in patients with ankylosing spondylitis, with the Bath Ankylosing Spondylitis Functional Index (BASFI) at 6 months of treatment as the primary outcome measure.",[26],{"date":119,"type":39},"2026-04-29",{"date":121,"type":39},"2026-01-19",{"date":123,"type":21},"2028-06-30",{"name":125,"class":46},"China-Japan Friendship Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100581002","the-disease-progression-of-chinese-axial-spondyloarthritis-in-a-real-word-cohort-study-100581002","NCT06844643","The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study","DPCASPA","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Diagnosis of axial spondyloarthritis (axSpA) according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria\n\nExclusion Criteria:\n\n* Presence of severe, unstable medical conditions that may interfere with the study assessments, including but not limited to:\n\nEnd-stage renal disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²) Severe cardiovascular disease Active malignancy or malignancy requiring ongoing treatment\n\n* Current diagnosis of schizophrenia, other psychotic disorders, severe cognitive impairment, or epilepsy with recurrent uncontrolled seizures, which, in the opinion of the investigator, may impair the ability to provide informed consent or comply with follow-up visits.\n* Pregnant or lactating women",{"count":134,"type":21},2250,"An observational, ambispective cohort to learn about the disease progression of axial spondyloarthritis (axSpA) according to the changes from baseline in measures of disease activity, function, and imaging.",[137,26],"Axial Spondyloarthritis","2026-04-10",{"date":140,"type":39},"2026-04-13",{"date":142,"type":39},"2025-03-01",{"date":144,"type":21},"2030-12-01",{"name":125,"class":46},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":160,"locationsCount":47},"100632137","integrated-traditional-chinese-and-western-medicine-for-ankylosing-spondylitis-as-a-cohort-study-protocol-focusing-on-spondyloarthritis-research-consortium-of-canada-sparcc-scoring-system-100632137","NCT07509775","Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System","Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis: A Cohort Study Protocol Focusing on Spondyloarthritis Research Consortium of Canada (SPARCC) Scoring System",{"count":153,"type":21},210,"This study is a multicentre, ambidirectional, observational cohort study. The ambidirectional design incorporates both the collection of retrospective data from the three years prior to enrolment, and a prospective follow-up period of up to two years. The study is designed to evaluate the long-term effects of Integrated Medicine on radiographic progression in patients diagnosed with Ankylosing spondylitis (AS).",[26],"2026-04-04",{"date":41,"type":39},{"date":121,"type":39},{"date":123,"type":21},{"name":125,"class":46},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":56,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":47},"100613108","deep-breathing-combined-with-core-stability-exercises-in-the-treatment-of-patients-with-ankylosing-spondylitis-100613108","NCT07262294","Deep Breathing Combined With Core Stability Exercises in the Treatment of Patients With Ankylosing Spondylitis","The Effect of Deep Breathing Added to Core Stability Exercises in the Treatment of Patients With Ankylosing Spondylitis: A Randomized Controlled Trial","RCT","Inclusion Criteria:\n\n* Receiving the same medical treatment\n* Age range between 20 and 45 years\n* Includes both male and female patients\n* Diagnosed with stable ankylosing spondylitis (AS) for at least 3 months\n* Not engaged in any other rehabilitation programs within the last 6 months\n\nExclusion Criteria:\n\n* Presence of other systemic or neurological disorders\n* Any change in medication within the last 6 months","25 Years","45 Years",{"count":172,"type":21},30,[58],"Exercise may be considered the gold standard for the management of mechanical and functional symptoms associated with patients having AS and they are considered as a safe and effective treatment for improving strength, spinal mobility, and physical fitness in general. However, there were no definite types or doses recommended over others.\n\nAdditionally, poor posture is one of the consequences of AS due to pain, loss of flexibility, and muscular weakness which may also affect respiratory function. This faulty mechanical posture of the thoracic and cervical spine may affect the pulmonary function of these patients. Therefore, the purpose of the current study is to investigate the efficacy of deep breathing exercises added to core stability exercises in the treatment of patients suffering from AS.",[26],"2026-03-06",{"date":178,"type":39},"2026-03-09",{"date":180,"type":39},"2026-02-01",{"date":182,"type":21},"2026-12-30",{"name":184,"class":46},"Beni-Suef University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":56,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100462562","phase-4-a-study-evaluating-the-efficacy-of-secukinumab-300mg-in-chinese-adults-with-active-ankylosing-spondylitis-100462562","NCT05303285","A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis","A Multicenter Study Evaluating the Efficacy and Safety of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis.","Inclusion Criteria:\n\n* Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.\n* Participant must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \\>= 4 and a Patient's Assessment of ●Total Back Pain score \\>= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.\n* Participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs as defined by the Investigator.\n* If entering the study on concomitant methotrexate (MTX), leflunomide, sulfasalazine (SSZ), and\u002For hydroxychloroquine, participant must be on a stable dose of MTX (\\\u003C= 25 mg\u002Fweek) and\u002For SSZ (\\\u003C= 3 g\u002Fday) and\u002For hydroxychloroquine (\\\u003C= 400 mg\u002Fday) or leflunomide (\\\u003C= 20 mg\u002Fday) for at least 28 days prior to the Baseline visit. A combination of up to two background conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and leflunomide.\n* If entering the study on concomitant oral corticosteroids, participant must be on a stable dose of prednisone (\\\u003C= 10 mg\u002Fday), or oral corticosteroid equivalents, for at least 14 days prior to the Baseline visit.\n* If entering the study on concomitant NSAIDs, tramadol, combination of acetaminophen and codeine or hydrocodone, and\u002For non-opioid analgesics, participant must be on stable dose(s) for at least 14 days prior to the Baseline visit.\n\nExclusion Criteria:\n\n* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).\n* Prior exposure to any biologic therapy with a potential therapeutic impact on spondyloarthritis (SpA).\n* Intra-articular joint injections, spinal\u002Fparaspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline visit. Inhaled or topical corticosteroids are allowed.\n* Participant on any other DMARDs (other than those allowed), thalidomide or apremilast within 28 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.\n* Participant on opioid analgesics (except for combination acetaminophen\u002Fcodeine or acetaminophen\u002Fhydrocodone which are allowed) or use of inhaled marijuana within 14 days prior to the Baseline visit.\n* Participant has a history of inflammatory arthritis of different etiology other than axial SpA (including but not limited to rheumatoid arthritis, psoriatic arthritis, mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age.\n* Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase \\> 2 × upper limit of normal (ULN); serum alanine transaminase \\> 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula \\\u003C 40 milliliter (mL)\u002Fminute\u002F1.73m\\^2; hemoglobin \\\u003C 10 gram\u002Fdeciliter, total white blood cell count \\\u003C 2,500\u002Fmicroliter (μL); absolute neutrophil count \\\u003C 1,500\u002FμL; absolute lymphocyte count \\\u003C 800\u002FμL; and platelet count \\\u003C 100,000\u002FμL.","80 Years",{"count":194,"type":21},100,[196],"PHASE4","The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).",[26],"2026-01-25",{"date":201,"type":39},"2026-01-27",{"date":203,"type":39},"2024-06-14",{"date":205,"type":21},"2026-08-31",{"name":207,"class":46},"Tongji Hospital",3,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":15,"sex":16,"minAge":216,"maxAge":4,"enrollmentInfo":217,"targetDuration":219,"studyType":22,"phases":4,"briefSummary":220,"conditions":221,"keywords":264,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":47},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform","2 Years",{"count":218,"type":21},10000,"10 Years","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[222,223,224,225,90,26,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[240,265,266,267,268,269,270,271,272,273,223,274,275,276,277,278,242,279,280,281,282,283,284,285,286],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":289,"type":39},"2026-01-22",{"date":291,"type":39},"2023-07-05",{"date":293,"type":21},"2030-12-31",{"name":295,"class":46},"Brain Inflammation Collaborative",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":56,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":314,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":47},"100618088","the-effect-of-exercise-on-serum-irisin-levels-and-clinical-parameters-in-patients-with-axial-spondyloarthritis-100618088","NCT07327073","The Effect of Exercise on Serum Irisin Levels and Clinical Parameters in Patients With Axial Spondyloarthritis.","The Effect of High-intensity Intermittent Exercise and Moderate-intensity Continuous Exercise on Serum Irisin Levels, Disease Activity, Functional Status, and Quality of Life in Patients With Axial Spondyloarthritis: a Prospective, Randomized Study","Inclusion Criteria:\n\n* Patients diagnosed with axillary spondyloarthropathy according to ASAS diagnostic criteria,\n* Having a high disease severity (ASDAS-CRP above 2.1),\n* Being sedentary (not engaging in physical activity at least 3 days a week in the last 3 months),\n* Having no change in ankylosing spondylitis medical treatment in the last 3 months,\n* Not having any orthopedic, neurological, cardiovascular, or mental disease that would affect exercise,\n* Not using any assistive devices for ambulation,\n* Having a BMI of 25 kg\u002Fm2 or less,\n* Male and female patients aged 18-50 years.\n\nExclusion Criteria:\n\n* Those with uncontrolled cardiopulmonary disease (such as hypertension, chronic obstructive pulmonary disease, heart failure),\n* Having comorbidities that reduce exercise capacity,\n* Pregnancy,\n* Malignancy,\n* Those with a recent history of surgery,\n* Those who have engaged in regular exercise (aquatic exercise, land exercise, etc.) in the previous 3 months","50 Years",{"count":305,"type":21},75,[58],"This study aimed to investigate the effects of high-intensity intermittent exercise and moderate-intensity continuous exercise on serum irisin levels, disease activity, functional status, and quality of life in patients with axial spondyloarthritis.",[26,309],"Irisin",[311,312,313],"ankylosing spondylitis","exercise","irisin","NOT_YET_RECRUITING","2026-01-09",{"date":317,"type":39},"2026-01-12",{"date":319,"type":21},"2026-01-30",{"date":321,"type":21},"2026-05-30",{"name":323,"class":46},"Kirsehir Ahi Evran Universitesi",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":56,"phases":333,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":314,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100602803","the-effect-of-laughter-yoga-on-patients-with-ankylosing-spondylitis-100602803","NCT07128264","The Effect of Laughter Yoga on Patients With Ankylosing Spondylitis","The Effect of Laughter Yoga on Patients With Ankylosing Spondylitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Those diagnosed with ankylosing spondylitis,\n* Those who scored 10 or above on the depression scale, 8 or above on the anxiety scale, and 15 or above on the stress scale of the Depression-Anxiety-Stress Scale\n* Are over 18 years of age,\n* Have no hearing or communication problems,\n* Possess a smartphone,\n* Have no physical problems that would prevent them from performing yoga exercises (bleeding hemorrhoids, any type of hernia, persistent cough, incontinence, hypertension, major psychiatric disorders, pregnancy, flu, epilepsy, or surgery within the last 3 months, etc.)\n* Ankylosing spondylitis patients who volunteer to participate in the study will be included in the study sample.\n\nExclusion Criteria:\n\n* Patients who do not participate in laughter yoga\n* Patients who wish to withdraw from the study",{"count":332,"type":21},60,[58],"This study will be conducted to evaluate the effects of laughter yoga on disease activity, pain, functional status, depression\u002Fanxiety\u002Fstress, and quality of life in ankylosing spondylitis patients.",[26],[337],"Ankylosing spondylitis(AS),Nursing,Pain,Depression\u002Fanxiety\u002Fstress,Laughter yoga","2025-08-13",{"date":340,"type":39},"2025-08-17",{"date":342,"type":21},"2025-08-29",{"date":344,"type":21},"2026-04",{"name":346,"class":46},"Ataturk University",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":47},"100572907","the-relationship-between-arterial-stiffness-and-pulmonary-and-extrapulmonary-features-in-ankylosing-spondylitis-100572907","NCT06739369","The Relationship Between Arterial Stiffness and Pulmonary and Extrapulmonary Features in Ankylosing Spondylitis","Investigation of the Relationship Between Arterial Stiffness and Pulmonary and Extrapulmonary Features in Patients With Ankylosing Spondylitis","Inclusion Criteria:\n\n* Diagnosis of ankylosing spondylitis according to ASAS diagnostic criteria\n* Being aged 18-65\n* Stable medication use for at least 3 months\n* Voluntary participation in the study\n\nExclusion Criteria:\n\n* Having uncontrolled cardiopulmonary disease\n* Being pregnant\n* Having undergone recent surgery\n* Presence of malignancy\n* Failure to perform to assessments","85 Years",{"count":356,"type":21},25,"The aim of this study was to investigate the relationship between arterial stiffness and pulmonary and extrapulmonary features in patients with ankylosing spondylitis.",[26],"2025-08-10",{"date":361,"type":39},"2025-08-12",{"date":363,"type":39},"2025-08-06",{"date":365,"type":21},"2026-12",{"name":323,"class":46},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":56,"phases":377,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":394},"100570434","phase-4-effect-and-safety-of-benzathine-penicillin-combined-with-etanercept-on-spondyloarthritis-100570434","NCT06707194","Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis","Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis: a Multicenter Randomized Controlled Clinical Study","Inclusion Criteria:\n\nThe following patients would be included: (1) The subjects voluntarily participate and sign an informed consent form; (2) patients aged 18-59 years; (3) According to the following guidelines or diagnostic criteria, a standardized diagnosis of spinal arthritis patients is made, which meets one of the following diagnostic criteria: ① 2009 ASAS classification criteria for axial spinal arthritis; ② Classification criteria for ASAS peripheral spondyloarthritis in 2011. And subjects with spinal arthritis who are in a relatively active period (ASDAS-CRP\\>1.2 )of infection;\n\nExclusion Criteria:\n\nhe exclusion criteria are as follows: (1) Subjects with nasopharyngitis, active tuberculosis, inflammatory bowel disease and other infections, other rheumatic and immune diseases, malignant tumors, and concomitant bone and joint diseases; (2) Individuals who are allergic to the components of the experimental drug; (3)Severe abnormalities in liver and kidney function (liver enzymes ≥ 2 times normal; creatinine ≥ 2 times normal); (4)Pregnant, preparing for pregnancy or breastfeeding women; (5)Moderate to severe heart failure (New York Heart Association grades 3-4); (6)Some researchers believe that other situations are not suitable for the use of etanercept or other experimental drugs; (7)Active gastrointestinal ulcer\u002Fbleeding; (8) According to the researcher's judgment, it is not suitable to participate in this study; (9)Patients in the acute phase of streptococcal infection: present with clinical manifestations of acute pharyngitis, acute tonsillitis, scarlet fever, and streptococcal pyoderma, and ASO or ADNS\\>normal range, and\u002For CRP\\>normal range.","59 Years",{"count":376,"type":21},340,[196],"The purpose of the study is to verify the clinical feasibility of Benzathine penicillin (BPG) \u002FEtanercept (ETN) combination regimen in patients with spondyloarthritis (SpA) and at the same time compare Benzathine penicillin \u002FEtanercept combination regimen and Etanercept maintenance therapy in reducing disease activity, improving patients' clinical symptoms and body function scores, enhancing quality of life, improving imaging performance and safety.",[380,26],"Spondyloarthritis (SpA)",[382,383,384],"spondyloarthritis","benzathine penicillin","Etanercept","2025-06-23",{"date":387,"type":39},"2025-06-26",{"date":389,"type":39},"2025-06-14",{"date":391,"type":21},"2027-07-31",{"name":393,"class":46},"Nanfang Hospital, Southern Medical University",6,{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":219,"maxAge":374,"enrollmentInfo":402,"targetDuration":404,"studyType":22,"phases":4,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":47},"100592083","bidirectional-cohort-study-of-nanfang-spondyloarthritis-100592083","NCT06988813","Bidirectional Cohort Study of Nanfang Spondyloarthritis","BCNS","Inclusion Criteria:\n\n* 1.Attended Nanfang Hospital, Southern Medical University, 2010-2030 2.Prospective cohort study component: subjects voluntarily participate with informed consent and sign an informed consent form 3.Retrospective cohort study: (i) patients who visited the hospital from April 2010 to April 2024 (and who will not return to the hospital at a later date) were exempted from informed consent; (ii) patients who visited the hospital from May 2024 to April 2025 were required to sign an informed consent 4.10 years old ≤ age ≤ 59 years old 5.Patients with a standardized diagnosis of spondyloarthritis by the following guidelines or diagnostic criteria, i.e., meeting one of the following diagnostic criteria: (1) 2009 ASAS classification criteria for axial spondyloarthritis; (2) 2011 ASAS classification criteria for peripheral spondyloarthritis\n\nExclusion Criteria:\n\n* 1\\. Women who are pregnant, preparing for pregnancy or breastfeeding 2.Moderate to Severe Heart Failure (New York Heart Association Class 3-4) 3.Active peptic ulcers\u002Fbleeding 4.Judged by the investigator to be unsuitable for participation in this study",{"count":403,"type":21},3000,"4 Years","Spondyloarthritis（SpA） patients attending Nanfang Hospital of Southern Medical University will generate a large number of clinical condition scales, laboratory indicators, imaging data such as X-rays or MRIs in the course of multiple standardized follow-up visits, as well as medical specimens from some of the patients who undergo surgical treatments. The Department of Orthopaedic Surgery of Nanfang Hospital is looking forward to the future and proposes to establish a specialized cohort named \"Nanfang SpA Bidirectional Specialized Disease Cohort\" by simply recording the clinical and imaging data of the above patients who have attended the clinic, been treated routinely, and have been followed up in the department without any interventional research measures. The cohort is proposed to: (1) archive the disease characteristics, biochemical index data, and disease assessment scales of all SpA patients attending the Southern Hospital; (2) record the X-ray and magnetic resonance imaging data of the patients to establish the \"Southern SpA Imaging Dataset\". This provides strong support for subsequent SpA research projects and lays the foundation for subsequent large-scale transect studies and retrospective studies.",[380,26],[408],"Bidirectional Cohort","2025-05-16",{"date":411,"type":39},"2025-05-25",{"date":413,"type":21},"2025-05-17",{"date":415,"type":21},"2030-04-30",{"name":393,"class":46},{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":314,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":47},"100574997","a-registry-study-assessing-pro-dosing-patterns-and-safety-of-vunakizumab-in-patients-with-general-rheumatic-diseases-100574997","NCT06766552","A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","A Multicenter Registry Study Assessing Patient Reported Outcome, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","V-MIRACLE","Inclusion Criteria:\n\n1. Diagnosed with rheumatic autoimmune diseases such as ankylosing spondylitis\u002Fradiologically negative axial spondyloarthritis\u002Fpsoriatic arthritis\u002Fpolymyalgia rheumatica\u002FTakayasu arteritis\u002Fgiant cell arteritis\u002F non-ocular Behcet's disease\u002F enthesitis-related arthritis;\n2. Currently receiving or planning to receive fulvezinib treatment;\n3. Can follow up according to the doctor's advice;\n4. Able to understand and sign the informed consent form, understand the purpose of this study, and voluntarily participate in this study.\n\nExclusion Criteria:\n\n1.Investigator believes will prevent the subject from following and completing the study protocol",{"count":218,"type":21},"Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are common diseases in rheumatology. Traditional anti-rheumatic drugs are less effective and have greater side effects than biological agents. At present, there has been no large-scale registration study on rheumatic autoimmune diseases such as spondyloarthritis in China. However, data such as patient characteristics, medication patterns, and patient outcome reports of different rheumatology diseases can often serve as a reference for rheumatology clinicians to reasonably select treatment methods for different patients. Therefore, a large-scale registration study is needed to fill the gap in multi-disease registration studies in rheumatology departments in China.",[26,90,428,429,430,431,432,433],"Nr-axSpA","Polymyalgia Rheumatica (PMR)","Takayasu Arteritis (TAK)","Giant Cell Arteritis (GCA)","Behcet's Disease","Enthesitis-related Arthritis","2025-01-08",{"date":436,"type":39},"2025-01-09",{"date":438,"type":21},"2025-01-30",{"date":440,"type":21},"2030-06-30",{"name":442,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":450,"targetDuration":452,"studyType":22,"phases":4,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":47},"100566057","cardiovascular-disease-risk-factors-and-healthy-lifestyle-behaviours-in-patients-with-ankylosing-spondylitis-100566057","NCT06650228","Cardiovascular Disease Risk Factors and Healthy Lifestyle Behaviours in Patients with Ankylosing Spondylitis","Assessment of Knowledge of Cardiovascular Disease Risk Factors and Healthy Lifestyle Behaviours in Patients with Ankylosing Spondylitis","Inclusion Criteria:\n\n* Diagnosis of ankylosing spondylitis according to ASAS diagnostic criteria\n* Being aged 18-65\n* Stable medication use for at least 3 months\n* Voluntary participation in the study\n\nExclusion Criteria:\n\n* Having uncontrolled cardiopulmonary disease\n* Being pregnant\n* Having undergone recent surgery\n* Presence of malignancy",{"count":451,"type":21},42,"1 Day","A review of the literature did not identify any studies that assessed knowledge of cardiovascular disease risk factors and healthy lifestyle behaviours in patients with ankylosing spondylitis. The aim of this study is to assess knowledge of cardiovascular disease risk factors, healthy lifestyle behaviours and physical activity levels in patients with ankylosing spondylitis.",[26],"2024-10-23",{"date":457,"type":39},"2024-10-26",{"date":459,"type":39},"2024-10-22",{"date":461,"type":21},"2025-12",{"name":323,"class":46}]